{"preliminary_commentary":{"by_channel":{"x_thread":3},"note":"Preliminary. Indexed podcasts, YouTube videos and X posts that name this trial so far. A report screens them, searches for more and cites what clinicians said when it is built, so final coverage is set at build."},"free_build":{"available":false},"name":"NCT04674813","nct_id":"NCT04674813","offer":{"currency":"USD","how":"Order at https://www.erudio.com/contact?report=nct04674813. The price is an estimate of verified statements from the commentary indexed so far, fixed at order. Final coverage is set when the report is built. We build the report within 24 hours of confirming the order and deliver it when it passes our checks; if it cannot be built to our standard, nothing is charged.","price_usd":750,"size":"focused","size_rule":"Focused: 1–150 verified statements, estimated at 14 per indexed commentary source"},"registry":{"acronym":null,"arms":[{"description":null,"label":"Administration of CC-95266","type":"EXPERIMENTAL"}],"collaborators":[],"completion_date":{"date":"2025-12-22","type":"ACTUAL"},"conditions":["Multiple Myeloma"],"enrollment":{"count":130,"type":"ACTUAL"},"has_results":false,"interventions":[{"name":"CC-95266","otherNames":[],"type":"DRUG"},{"name":"Fludarabine","otherNames":[],"type":"DRUG"},{"name":"Cyclophosphamide","otherNames":[],"type":"DRUG"},{"name":"Bendamustine","otherNames":[],"type":"DRUG"}],"last_update":"2026-02-09","lead_sponsor":"Juno Therapeutics, a Subsidiary of Celgene","official_title":"A Phase 1, Multicenter, Open-Label Study of CC-95266 in Subjects With Relapsed and/or Refractory Multiple Myeloma","overall_status":"COMPLETED","phases":["PHASE1"],"primary_completion_date":{"date":"2025-12-22","type":"ACTUAL"},"primary_outcomes":[{"measure":"Number of participants with Adverse Events (AEs)","timeFrame":"Up to 2 years after CC-95266 infusion"},{"measure":"Number of participants with significant laboratory abnormalities","timeFrame":"Up to 2 years after CC-95266 infusion"},{"measure":"Number of participants with Dose Limiting Toxicities (DLTs)","timeFrame":"Up to 2 years after CC-95266 infusion"},{"measure":"Maximum Tolerated Dose (MTD)","timeFrame":"Up to 2 years after CC-95266 infusion"},{"measure":"Recommended Phase 2 Dose (RP2D)","timeFrame":"Up to 2 years after CC-95266 infusion"}],"references":[{"citation":"Bal S, Htut M, Nadeem O, Anderson LD Jr, Gregory T, Kocoglu MH, Rossi AC, Martin T, Egan DN, Costa LJ, Hu H, Chen J, Li S, Kelly LM, Sarkis N, Ziyad S, Jordahl KM, Kao WM, Kaeding AJ, Burgess MR, Berdeja JG. Arlocabtagene autoleucel: a GPRC5D-targeted CAR T-cell therapy for heavily pretreated relapsed/refractory multiple myeloma. Blood. 2026 Sep 3;148(10):1240-1250. doi: 10.1182/blood.2025030750.","pmid":"42233419","type":"DERIVED"}],"start_date":{"date":"2021-02-24","type":"ACTUAL"},"study_type":"INTERVENTIONAL","title":"A Study of CC-95266 in Participants With Relapsed and/or Refractory Multiple Myeloma","url":"https://clinicaltrials.gov/study/NCT04674813"},"report":null,"schema_id":"erudio.trial_listing","schema_version":"3.0","state":"listed","state_text":"No report yet. It can be ordered.","url":"https://www.erudio.com/trials/nct04674813"}